Resultado de búsqueda
31 de oct. de 2023 · At Asher Biotherapeutics, we are pioneering a new approach with our cis‑targeted immunotherapies. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response.
31 de oct. de 2023 · New Preclinical Data for AB821, Asher Bio’s CD8-Targeted IL-21. In a poster presentation entitled, “AB821 is a CD8 + T cell selective IL-21 with enhanced bioavailability that reduces CD8 + T cell exhaustion to induce potent antitumor activity,” lead author Renee Greer, Ph.D., Principal Scientist at Asher Bio, described new ...
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune...
23 de mar. de 2021 · Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform. – Cis-targeting technology aims to enable precise targeting of discrete beneficial immune cell subtypes with a novel class of biotherapeutics and avoid unwanted ...